| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2007PNAS..104.4624D |
| P356 | DOI | 10.1073/PNAS.0608657104 |
| P932 | PMC publication ID | 1838651 |
| P698 | PubMed publication ID | 17360574 |
| P5875 | ResearchGate publication ID | 6445814 |
| P50 | author | Gerald Pier | Q38326393 |
| P2093 | author name string | Joanna B Goldberg | |
| Jayasimha Rao | |||
| Antonio DiGiandomenico | |||
| Jason Gardner | |||
| Alice N Neely | |||
| Tanweer S Zaidi | |||
| Katie Harcher | |||
| P2860 | cites work | Pseudomonas aeruginosa galU is required for a complete lipopolysaccharide core and repairs a secondary mutation in a PA103 (serogroup O11) wbpM mutant | Q28492943 |
| Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model | Q30435195 | ||
| Regional specialization in the mucosal immune system: what happens in the microcompartments? | Q33594113 | ||
| Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread | Q33596653 | ||
| Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains | Q33757770 | ||
| O-Antigen Serotypes and Type III Secretory Toxins in Clinical Isolates of Pseudomonas aeruginosa | Q34991119 | ||
| Clearance of Pseudomonas aeruginosa from the murine gastrointestinal tract is effectively mediated by O-antigen-specific circulating antibodies | Q35426022 | ||
| Rapid and sensitive method for evaluating Pseudomonas aeruginosa virulence factors during corneal infections in mice | Q35436945 | ||
| Application of vaccine technology to prevention of Pseudomonas aeruginosa infections. | Q36284542 | ||
| Cloning and surface expression of Pseudomonas aeruginosa O antigen in Escherichia coli | Q37294311 | ||
| Cystic fibrosis transmembrane conductance regulator-mediated corneal epithelial cell ingestion of Pseudomonas aeruginosa is a key component in the pathogenesis of experimental murine keratitis | Q39510212 | ||
| Lipopolysaccharide and high-molecular-weight polysaccharide serotypes of Pseudomonas aeruginosa | Q40263015 | ||
| Prophylaxis and therapy of Pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients. | Q40463908 | ||
| Genotypic and phenotypic characteristics of Pseudomonas aeruginosa isolates associated with ulcerative keratitis | Q43478900 | ||
| Frequency of Pseudomonas aeruginosa serotypes in burn wound infections and their resistance to antibiotics | Q44019509 | ||
| Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis | Q44060947 | ||
| Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model | Q44717986 | ||
| Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection | Q47969223 | ||
| Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group | Q71434752 | ||
| Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis | Q71512417 | ||
| Circulating levels of tumour necrosis factor, interleukin 6 and proteolytic activity in a murine model of burn and infection | Q71761835 | ||
| Integration-proficient Pseudomonas aeruginosa vectors for isolation of single-copy chromosomal lacZ and lux gene fusions | Q73206292 | ||
| Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection | Q73434677 | ||
| Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa | Q83115532 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Pseudomonas aeruginosa | Q31856 |
| polysaccharide | Q134219 | ||
| immunization | Q1415366 | ||
| P304 | page(s) | 4624-4629 | |
| P577 | publication date | 2007-03-05 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections | |
| P478 | volume | 104 |
| Q43121719 | A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa. |
| Q38940907 | A multifunctional bispecific antibody protects against Pseudomonas aeruginosa |
| Q30408273 | A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models |
| Q34795807 | Acinetobacter baumannii: emergence of a successful pathogen |
| Q36968815 | Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis. |
| Q33564290 | Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections |
| Q90117791 | CCN1 is an opsonin for bacterial clearance and a direct activator of Toll-like receptor signaling |
| Q37713368 | Catheter-associated urinary tract infection by Pseudomonas aeruginosa is mediated by exopolysaccharide-independent biofilms. |
| Q30415438 | Construction of mobilizable mini-Tn7 vectors for bioluminescent detection of gram-negative bacteria and single-copy promoter lux reporter analysis |
| Q46091425 | Cross reaction between proteins from Larrea divaricata Cav. (jarilla) and cellular and extracellular proteins of Pseudomonas aeruginosa |
| Q89170079 | Enhancing IgG distribution to lung mucosal tissue improves protective effect of anti-Pseudomonas aeruginosa antibodies |
| Q33613907 | Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines. |
| Q37891784 | Genetic and Functional Diversity of Pseudomonas aeruginosa Lipopolysaccharide |
| Q36147444 | Genetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against Pseudomonas aeruginosa infections |
| Q36095081 | Global challenge of multidrug-resistant Acinetobacter baumannii |
| Q34291197 | Glycosylation of pilin and nonpilin protein constructs by Pseudomonas aeruginosa 1244 |
| Q30423024 | Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening |
| Q50583511 | Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. |
| Q45174642 | Immunization with Bivalent Flagellin Protects Mice against Fatal Pseudomonas aeruginosa Pneumonia. |
| Q36539114 | Immunization with a Pseudomonas aeruginosa 1244 pilin provides O-antigen-specific protection |
| Q36676050 | Immunoproteomics: the key to discovery of new vaccine antigens against bacterial respiratory infections. |
| Q42215058 | In vivo imaging of bioluminescent Pseudomonas aeruginosa in an acute murine airway infection model. |
| Q42119085 | Indole and 7-hydroxyindole diminish Pseudomonas aeruginosa virulence |
| Q44289404 | Intranasal immunization with a non-adjuvanted adhesive protein descended from Pasteurella pneumotropica and its preventive efficacy against opportunistic infection in mice. |
| Q30441316 | Lipopolysaccharide O-antigen chain length regulation in Pseudomonas aeruginosa serogroup O11 strain PA103. |
| Q92026612 | Lung infection caused by Pseudomonas aeruginosa in a CD26/DPP4 deficient F344 rat model |
| Q64069605 | Mechanistic research holds promise for bacterial vaccines and phage therapies for |
| Q37111626 | Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria |
| Q36945838 | Needle-free vaccine delivery |
| Q36487854 | Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide |
| Q37937369 | Recent developments for Pseudomonas vaccines |
| Q30279061 | Recombinant Salmonella Expressing Burkholderia mallei LPS O Antigen Provides Protection in a Murine Model of Melioidosis and Glanders |
| Q36391313 | Recombinant outer membrane protein F-B subunit of LT protein as a prophylactic measure against Pseudomonas aeruginosa burn infection in mice |
| Q36594009 | Subcutaneous vaccination with attenuated Salmonella enterica serovar Choleraesuis C500 expressing recombinant filamentous hemagglutinin and pertactin antigens protects mice against fatal infections with both S. enterica serovar Choleraesuis and Bord |
| Q27313397 | The Role of CHI3L1 (Chitinase-3-Like-1) in the Pathogenesis of Infections in Burns in a Mouse Model |
| Q30441643 | Vaccination against Pseudomonas aeruginosa pneumonia in immunocompromised mice |
| Q28266964 | Vaccines and immunotherapy against Pseudomonas aeruginosa |
| Q26852817 | Vaccines for Pseudomonas aeruginosa: a long and winding road |
Search more.